B4GALT7 Antibody - BSA Free

Immunohistochemistry-Paraffin: B4GALT7 Antibody [NBP1-88652] -

Immunohistochemistry-Paraffin: B4GALT7 Antibody [NBP1-88652] - Staining of human kidney shows moderate granular cytoplasmic positivity in cells in tubules.

Immunohistochemistry-Paraffin: B4GALT7 Antibody [NBP1-88652] -

Immunohistochemistry-Paraffin: B4GALT7 Antibody [NBP1-88652] - Staining of human skin shows no positivity in squamous epithelial cells as expected.

Western Blot: B4GALT7 Antibody - BSA Free [NBP1-88652] -

Down-regulation of B4GALT7 results in DNA damage and arrests the cell cycle at the G2/M phase.(A–B) p-ATM and p-H2A. X protein levels in SNU-423 and SK-Hep-1 cells transfected with shB4GALT7 or shNC, and further transfected with pEX-3/B4GALT7 or pEX-3/vector. (C) Cell cycle analysis in SNU-423 and SK-Hep-1 cells after shRNA mediated B4GALT7 inhibition. Mean +/- SD for three independent experiments are demonstrated. (D–E) p-Chk2, p-Wee1, p-cdc2 and cyclin B1 protein levels in B4GALT7-downregulation SNU-423 and SK-Hep-1 cells, and further transfected with pEX-3/B4GALT7 or pEX-3/vector. *, P < 0.05; **, P < 0.01. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38025683), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: B4GALT7 Antibody - BSA Free [NBP1-88652] -

B4GALT7 is highly expressed in HCC tissues.(A) B4GALT7 expression levels in three GEO datasets, GSE14520, GSE25097 and GSE84402. (B) B4GALT7 levels in the TCGA database. (C) Survival probability of HCC patients with different expression of B4GALT7. The expression of B4GALT7 was analyzed by (D) western blotting and (E) real-time PCR in 10 pairs HCC samples and para-tumor specimens. (F) Representative immunohistochemical staining results of B4GALT7 based on the HPA database. (G) The expression landscape of B4GALT7 in the TIMER2.0 database. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38025683), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: B4GALT7 Antibody - BSA Free [NBP1-88652] -

The effects of B4GALT7 and miR-338-3p on HCC cell invasion.(A) Matrigel-based transwell assay was conducted in HCC cells transfected with pEX-3/vector, pEX-3/B4GALT7, and co-transfected with pEX-3/B4GALT7 and miR-338-3p mimics. (B) Western blotting assay revealed the expression levels of EMT marker proteins can be reversed when co-transfected with pEX-3/B4GALT7 and miR-338-3p mimics. (C) Representative western blots of EMT marker protein levels in SNU-423 cells transfected with shB4GALT7 or shNC, and further transfected with pEX-3/B4GALT7 or pEX-3/vector. *, P < 0.05; **, P < 0.01. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38025683), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: B4GALT7 Antibody - BSA Free [NBP1-88652] -

Down-regulation of B4GALT7 inhibits HCC cell proliferative abilities in vitro.(A) qPCR and (B) Western blotting analysis of the expression of B4GALT7 in HCC cells (SNU-423, SMMC-7721, SK-Hep-1, HepG2, Huh-7) and normal liver cell HL-7702. (C) Representative pictures of the green fluorescence intensity of HCC cells after transfected with shRNA vectors to mediate B4GALT7 inhibition. (D) qPCR and (E) Western blotting analysis of B4GALT7 expression in HCC cells after transfected as in C. Down-regulation of B4GALT7 inhibits the proliferative abilities of HCC cells (SNU-423, SK-Hep-1) determined by (F) MTT assay and (G) Colony formation assay. (H) Representative pictures of flow cytometry analysis of apoptosis stained with Annexin V-APC and 7-AAD in HCC cells transfected as in C. Scale bar: 100 um. Mean +/- SD for three independent experiments are demonstrated. *, P < 0.05; **, P < 0.01. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38025683), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: B4GALT7 Antibody - BSA Free [NBP1-88652] -

Down-regulation of B4GALT7 inhibits HCC cell proliferative abilities in vitro.(A) qPCR and (B) Western blotting analysis of the expression of B4GALT7 in HCC cells (SNU-423, SMMC-7721, SK-Hep-1, HepG2, Huh-7) and normal liver cell HL-7702. (C) Representative pictures of the green fluorescence intensity of HCC cells after transfected with shRNA vectors to mediate B4GALT7 inhibition. (D) qPCR and (E) Western blotting analysis of B4GALT7 expression in HCC cells after transfected as in C. Down-regulation of B4GALT7 inhibits the proliferative abilities of HCC cells (SNU-423, SK-Hep-1) determined by (F) MTT assay and (G) Colony formation assay. (H) Representative pictures of flow cytometry analysis of apoptosis stained with Annexin V-APC and 7-AAD in HCC cells transfected as in C. Scale bar: 100 um. Mean +/- SD for three independent experiments are demonstrated. *, P < 0.05; **, P < 0.01. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38025683), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: B4GALT7 Antibody - BSA Free [NBP1-88652] -

The reciprocal suppression effects of B4GALT7 and miR-338-3p.(A) The potential interaction between B4GALT7 and miR-338-3p predicted by TargetScan. (B) Expression levels of miR-338-3p in HCC cells (SNU-423, SK-Hep-1) and normal liver cell HL-7702. (C) Dual luciferase reporter assay demonstrated the luciferase activities in HEK-293T and SNU-423 cells following the indicated transfection. (D–E) Expression levels of miR-338-3p in SNU-423 and SK-Hep-1 cells with B4GALT7 overexpression and after shRNA mediated B4GALT7 inhibition. (F–G) qPCR and (H) Western blotting analysis of B4GALT7 expression in SNU-423 and SK-Hep-1 cells after transfected with miR-338-3p mimics and inhibitor. *, P < 0.05; **, P < 0.01. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38025683), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: B4GALT7 Antibody - BSA Free [NBP1-88652] -

The effects of B4GALT7 and miR-338-3p on HCC cell invasion and migration.(A–B) Wound healing assay, matrigel-free and matrigel-based transwell assays were performed in SNU-423 and SK-Hep-1 cells transfected with shNC, shB4GALT7, and co-transfected with sh-B4GALT7 and the miR-338-3p inhibitor. Migration of the cells to the wound was photographed at 0 h and 48 h. Scale bar: 100 um. (C) Western blotting assay revealed the expression levels of EMT marker proteins and the phosphorylation status of signaling proteins can be rescued when co-transfected with sh-B4GALT7 and the miR-338-3p inhibitor. *, P < 0.05; **, P < 0.01. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38025683), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: B4GALT7 Antibody - BSA Free [NBP1-88652] -

The effects of B4GALT7 and miR-338-3p on HCC cell invasion.(A) Matrigel-based transwell assay was conducted in HCC cells transfected with pEX-3/vector, pEX-3/B4GALT7, and co-transfected with pEX-3/B4GALT7 and miR-338-3p mimics. (B) Western blotting assay revealed the expression levels of EMT marker proteins can be reversed when co-transfected with pEX-3/B4GALT7 and miR-338-3p mimics. (C) Representative western blots of EMT marker protein levels in SNU-423 cells transfected with shB4GALT7 or shNC, and further transfected with pEX-3/B4GALT7 or pEX-3/vector. *, P < 0.05; **, P < 0.01. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/38025683), licensed under a CC-BY license. Not internally tested by Novus Biologicals.